A Study of Imatinib and Docetaxel in Prostate Cancer
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness of two drugs, docetaxel and
Gleevec®(also called imatinib), in prostate cancer that no longer responds to hormone
therapy. The investigators are interested in finding out if the combination of these two
drugs is more effective than docetaxel alone in the treatment of prostate cancer.